Pith. sign in

REVIEW 2 cited by

Y-Mol: A Multiscale Biomedical Knowledge-Guided Large Language Model for Drug Development

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2410.11550 v1 pith:IXFYRHAW submitted 2024-10-15 cs.AI cs.CL

Y-Mol: A Multiscale Biomedical Knowledge-Guided Large Language Model for Drug Development

classification cs.AI cs.CL
keywords biomedicaldrugy-moldevelopmentknowledgeacrossmultiscaleprediction
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved
0 comments
Share X Bluesky LinkedIn Reddit HN
read the original abstract

Large Language Models (LLMs) have recently demonstrated remarkable performance in general tasks across various fields. However, their effectiveness within specific domains such as drug development remains challenges. To solve these challenges, we introduce \textbf{Y-Mol}, forming a well-established LLM paradigm for the flow of drug development. Y-Mol is a multiscale biomedical knowledge-guided LLM designed to accomplish tasks across lead compound discovery, pre-clinic, and clinic prediction. By integrating millions of multiscale biomedical knowledge and using LLaMA2 as the base LLM, Y-Mol augments the reasoning capability in the biomedical domain by learning from a corpus of publications, knowledge graphs, and expert-designed synthetic data. The capability is further enriched with three types of drug-oriented instructions: description-based prompts from processed publications, semantic-based prompts for extracting associations from knowledge graphs, and template-based prompts for understanding expert knowledge from biomedical tools. Besides, Y-Mol offers a set of LLM paradigms that can autonomously execute the downstream tasks across the entire process of drug development, including virtual screening, drug design, pharmacological properties prediction, and drug-related interaction prediction. Our extensive evaluations of various biomedical sources demonstrate that Y-Mol significantly outperforms general-purpose LLMs in discovering lead compounds, predicting molecular properties, and identifying drug interaction events.

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Forward citations

Cited by 2 Pith papers

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score.

  1. ToolMol: Evolutionary Agentic Framework for Multi-objective Drug Discovery

    cs.LG 2026-05 unverdicted novelty 6.0

    ToolMol integrates evolutionary algorithms with agentic LLMs and precise RDKit tools to optimize multi-objective drug properties, yielding ligands with over 10% better predicted binding affinity and 35% gains in absol...

  2. ToolMol: Evolutionary Agentic Framework for Multi-objective Drug Discovery

    cs.LG 2026-05 unverdicted novelty 5.0

    ToolMol is an evolutionary agentic framework that pairs multi-objective genetic algorithms with LLM tool-calling to generate drug-like ligands with over 10% better predicted binding affinity and 35% better ABFE scores...